BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-49@catalystbrief.girapphe.com
DTSTAMP:20261117T061551Z
LAST-MODIFIED:20261117T061551Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Readout: Pfizer — PF-06821497 [Feb 2027]
DESCRIPTION:Phase 3 primary completion: A Study to Learn About the Investig
 ational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who 
 Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVP
 RO-1)..\nSource: https://clinicaltrials.gov/study/NCT06551324\nhttps://cat
 alystbrief.girapphe.com/e/49?lang=en\nNot investment advice. Dates may cha
 nge.
URL:https://catalystbrief.girapphe.com/e/49?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
